Hoth Enters into Commercial Licensing Agreement with University of Maryland, Baltimore and Isoprene

Hoth Therapeutics, a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that Hoth Therapeutics, Inc. (Hoth) has entered into a Commercial Evaluation Sublicense and Option Agreement with the University of Maryland, Baltimore (UMB) and Isoprene Pharmaceuticals Inc.

The agreement grants Hoth complete evaluation and option rights in the Dermatology Evaluation Field to develop and commercialize therapeutic compounds for the treatment of dermatological conditions in humans. The licensing agreement stems from results reported by UMB relating to the effect Retinoic acid metabolism blocking agents (RAMBAs) offer in treating cancer and dermatology related issues. To view the published results of the research, please click here.

Mr. Robb Knie, Chief Executive Officer of Hoth, commented, “We are excited about the opportunity to evaluate these novel retinamides (Retinoic acid metabolism blocking agents or RAMBAs) for the treatment of dermatological diseases. The initial work done by the University of Maryland, Baltimore and Isoprene Pharmaceuticals has shown promising therapeutic results, and we look forward to working with these respected institutions as we continue to progress through the trial phase.”

“The partnership between UMB, Isoprene Pharmaceuticals, and Hoth Therapeutics is an example of how early-stage technology investment by UM Ventures, Baltimore can enhance the commercial viability of important new medical innovations emerging from academic research,” said Rana Quraishi, PhD, Director of new ventures at UMB.

“The collaboration between Hoth Therapeutics, University of Maryland, Baltimore, and Isoprene Pharmaceuticals is critical for the development of UMB’s unique novel retinamide small molecules as potential new therapeutics for a variety of dermatological diseases,” said Vincent C.O. Njar, PhD, lead scientific inventor and professor in the University of Maryland School of Medicine.